Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed in Children With Recurrent Malignancies
NCT00520936Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2007
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in osteosarcoma (OS), Ewing sarcoma, medulloblastoma and 4 more, sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants With Overall Tumor Response up to 1 year. Started Sep 2007; status: completed.
02
Drugs
pemetrexed
03
Conditions
osteosarcoma (OS)Ewing sarcomamedulloblastomaneuroblastomarhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT00520936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00520936.